http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
구소미 ( So My Koo ),박성우 ( Sung Woo Park ),박종숙 ( Jong Sook Park ),이준혁 ( June Hyuk Lee ),장안수 ( An Soo Jang ),김도진 ( Do Jin Kim ),박춘식 ( Choon Sik Park ),박상현 ( Sang Hyun Paik ),고은석 ( Eun Suk Koh ) 대한결핵 및 호흡기학회 2011 Tuberculosis and Respiratory Diseases Vol.70 No.1
Pulmonary siderosis is a pneumoconiosis caused by chronic iron inhalation. A diagnosis of pulmonary siderosis is based on a patient history of iron inhalation, on chest radiographic findings, and on accumulation of iron oxide in macrophages within the lung. A typical radiographic finding of pulmonary siderosis includes ill-defined micronodules that are diffusely distributed in the lung. We experienced a 52-year-woman with a 1.3×1.5-cm mass in the left upper lobe with multiple nodules in both lungs. Because the radiographic findings were atypical, we conducted a video-assisted thorascopic lung biopsy procedure to exclude the diagnosis of metastatic lung cancer. After confirming iron deposition in the lung tissue and knowing the patient`s occupational history of welding iron, we concluded that this was a case of pulmonary siderosis.
오동준 ( Dong Jun Oh ),구소미 ( So-my Koo ),김양기 ( Yang Ki Kim ),김기업 ( Ki Up Kim ),어수택 ( Soo-taek Uh ),김현조 ( Hyun Jo Kim ),김동원 ( Dong Won Kim ) 대한내과학회 2016 대한내과학회지 Vol.91 No.1
흡연연관 간질성 섬유증(SRIF)은 콜라젠 침착으로 인한 폐포 중격의 비후가 있고, 호흡세기관지염과 폐기종이 동반되어 있다는 것이 특징이다. 2010년도에 처음으로 SRIF 용어를 사용하기 시작하였으며, 임상, 조직, 영상 소견이 특발성폐섬유증과 구별되는 병리 소견이다. SRIF는 현재까지 국내에서 보고된 적 없으며, 세계적으로도 보고가 드물다. 저자들은 SRIF 3예를 1년간 추적 관찰하여 보고하는 바이다. Smoking-related interstitial fibrosis (SRIF) is characterized by marked alveolar septal fibrosis seen as distinct thick collagen bundles, along with emphysema and respiratory bronchiolitis. In 2010, SRIF was deemed a new entity that differed from idiopathic pulmonary fibrosis (IPF) clinically, pathologically, and radiologically. No case of SRIF has been reported in Korea and it is rare worldwide. Here, we report the 1-year follow-up of three cases of SRIF. (Korean J Med 2016;91:49-56)
혈전용해 치료를 시행한 광범위 및 아광범위 폐색전증 환자의 단기 사망률
조윤주 ( Yun Ju Cho ),구소미 ( So My Koo ),방덕원 ( Duk Won Bang ),김기업 ( Ki Up Kim ),어수택 ( Soo Taek Uh ),김양기 ( Yang Ki Kim ) 대한내과학회 2013 대한내과학회지 Vol.84 No.1
Background/Aims: The mortality rate following massive and submassive pulmonary embolism (PE) remains high despite thrombolytic therapy. Although thrombolytic therapy is considered a life-saving intervention in massive PE, it is only selectively indicated in patients without hypotension who are at high risk of developing hypotension. Little is known about its clinical outcome in Korea. Methods: We retrospectively reviewed the records of patients given thrombolytics for massive and submassive PE objectively confirmed with chest computed tomography at Soon Chun Hyang University Hospital, Seoul, Korea, from 1 January 2004 to 1 August 2011. The primary outcome of this study was 30-day mortality. Secondary outcomes were the incidence of major bleeding at 30 days, mortality at 90 days, and recurrent venous thromboembolism (VTE) at 90 days. Results: Thrombolytic therapy was performed in 21 patients: nine with massive and 12 with submassive PE. The overall 30-day mortality rate was 24% (5/21). The mortality rate in patients with massive PE was higher than that in patients with submassive PE (44% vs. 8%, respectively; p = 0.010). Mortality rates at 90 and 30 days were identical. The estimated causes of death were right ventricular failure in four patients and fatal bleeding in one patient. The median time to death from thrombolysis was 1 day (0-13 days). Major bleeding episodes occurred in three patients (14%), including fatal bleeding in one patient. There was no recurrent VTE at 90 days. Conclusions: Patients who underwent thrombolytic therapy for massive PE showed a higher 30-day mortality compared with patients with submassive PE. (Korean J Med 2013;84:62-70)
이지연 ( Ji-yeon Lee ),구소미 ( So My Koo ),박경아 ( Kyong Ah Park ),서유리 ( Yu Ri Seo ),김세훈 ( Se Hun Kim ),김양기 ( Yang Ki Kim ),김기업 ( Ki Up Kim ),황정화 ( Jung Hwa Hwang ),어수택 ( Soo Taek Uh ) 대한결핵 및 호흡기학회 2011 Tuberculosis and Respiratory Diseases Vol.71 No.6
Background: Lung abscess is necrosis of the pulmonary parenchyma caused by microbial infection. At present, clinical outcomes after treatment are good. However, the pulmonary parenchymal changes on the chest computed tomography (CT) after treatment are not well known. We studied the changes of pulmonary parenchyma on plane chest radiography and chest CT in patients with lung abscess following the administration of antibiotics. Methods: We retrospectively reviewed 39 patients who had lung abscess with or without combined pneumonia from January 2006 to July 2010. We studied the therapeutic response in plane chest radiography of them at 1, 2, or more than 3 months following treatment. If any chest CT of them during the study period, we reviewed. Results: Mean age of the patients was about 61.3±11.2. Mean duration of antibiotics administration was about 36.7±26.8 days. After 3 months of following plane chest radiography, 10 patients (36%) showed without residual sequelae among 28 patients. Findings from other patients showed decrease in densities (11 patients, 39%), fibrostreaky sequelae (4 patients, 14%) and bullae (3 patients, 10%). After more than 2 months, chest CT was checked only in 7 patients. Among the 7 patients, 4 patients showed no residual lesion, 3 patients showed decreased densities on plane chest radiography. Chest CT revealed fibrostreaky densities in 2 patients, ground glass opacities in 3 patients, bullous formation in 1 patient, and cystic bronchiectasis in 1 patient. Conclusion: After more than 2 months following treatment for lung abscess even though there were no lesions on plane chest radiography, chest CT showed fibrostreaky or ground glass opacity.